Form 4: Moleculin Biotech Executive Trades Common Stock

Donald H. Picker, Chief Science Officer of Moleculin Biotech, Inc., reported transactions involving restricted stock units and common stock.

Summary

• Donald H. Picker, Chief Science Officer of Moleculin Biotech, Inc. (MBRX), engaged in several transactions related to his beneficial ownership of the company's common stock.
• On June 20, 2026, Picker acquired 44 shares of common stock through the conversion of restricted stock units (RSUs). On the same date, 13 shares were withheld for tax payments upon the vesting of RSUs.
• On June 22, 2026, Picker acquired an additional 71 shares of common stock through the conversion of RSUs. On this date, 21 shares were withheld for tax payments upon the vesting of RSUs.
• Picker was granted 173 RSUs on June 20, 2022, which vest in four equal annual installments starting on the first anniversary of the grant date.
• Picker was also granted 283 RSUs on June 22, 2023, which vest in four equal annual installments starting on the first anniversary of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine executive stock transactions and tax withholdings rather than significant strategic or financial events.

Positives

• The reporting person, Donald H. Picker, acquired additional shares of common stock through the vesting of restricted stock units, indicating continued equity participation.
• The transactions reflect the normal course of equity compensation for a key executive.

Negatives

• Shares were withheld for tax payments upon the vesting of restricted stock units, which represents a reduction in the net shares acquired by the reporting person.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for executives and directors regarding their transactions in company stock. These filings provide transparency into insider activity, which can be a factor in investment analysis.

Stakeholder Impact

• Shareholders: The filing provides transparency into insider stock activity, which can inform their investment decisions.
• Employees: The transactions reflect the company's executive compensation structure involving stock awards.

Key Dates

Keywords

Form 4, SEC Filing, Moleculin Biotech, MBRX, Insider Trading, Stock Options, Restricted Stock Units, Beneficial Ownership, Executive Compensation